A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated nonsmall-cell lung cancer

Clinical Lung Cancer

Volumn 13, Issue 1, 2012, Pages 31-38

  Spira, Alexander I ^a   Iannotti, Nicholas O ^b   Savin, Michael A ^c   Neubauer, Marcus ^d   Gabrail, Nashat Y ^e   Yanagihara, Ronald H ^f   Zang, Edith A ^g   Cole, Patricia E ^g   Shuster, Dale ^g   Das, Asha ^g  

^a Virginia Cancer Specialists   (United States)

^b Hematology Oncology Associates of Treasure Coast   (United States)

^c TEXAS ONCOLOGY   (United States)

^d Kansas City Cancer Center   (United States)

^e Gabrail Cancer Center   (United States)

^f St Louise Hospital   (United States)

^g EISAI INC   (United States)

Author keywords

Chemotherapy; Halichondrin B; Microtubule; Monotherapy; Tubulin

Indexed keywords

ERIBULIN; GEMCITABINE; PEMETREXED; PLATINUM; TAXANE DERIVATIVE; VASCULOTROPIN INHIBITOR; VINCA ALKALOID;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASTHENIA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTRITIS; HUMAN; LARGE CELL CARCINOMA; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PANCYTOPENIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SEPSIS; STOMATITIS; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; FURANS; HUMANS; KETONES; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84855686899     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.06.010     Document Type: Conference Paper

References (22)

1. American Cancer Society What are the key statistics about lung cancer? http://www.cancer org/Cancer/LungCancer-Non-SmallCell/DetailedGuide/non-small- cell-lung-cancer-key-statistics Accessed: December 1, 2010
2. American Cancer Society Cancer Facts and Figures 2008 http://www.cancer org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-figures-2008 Accessed: December 1, 2010
3. F. Fossella, J.R. Pereira, J. von Pawel Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group J Clin Oncol 21 2003 3016 3024 (Pubitemid 46606280)
4. K. Kelly, J. Crowley, P.A. Bunn Jr Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non - small-cell lung cancer: a Southwest Oncology Group trial J Clin Oncol 19 2001 3210 3218 (Pubitemid 32591438)
5. J.H. Schiller, D. Harrington, C.P. Belani Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98 (Pubitemid 34438899)
6. N. Hanna, F.A. Shepherd, F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597 (Pubitemid 41079796)
7. F.A. Shepherd, P.J. Rodrigues, T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132 (Pubitemid 41058344)
8. Y. Hirata, D. Uemura Halichondrins: antitumor polyether macrolides from a marine sponge Pure Appl Chem 58 1986 701 710 (Pubitemid 16557441)
9. M.A. Jordan, K. Kamath, T. Manna The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth Mol Cancer Ther 4 2005 1086 1095 (Pubitemid 41079102)
10. M.J. Towle, K.A. Salvato, J. Budrow In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B Cancer Res 61 2001 1013 1021 (Pubitemid 32174419)
11. T. Okouneva, O. Azarenko, L. Wilson Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase Mol Cancer Ther 7 2008 2003 2011
12. G. Kuznetsov, M.J. Towle, H. Cheng Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389 Cancer Res 64 2004 5760 5766 (Pubitemid 39095575)
13. G. Kuznetsov, K. TenDyke, M.J. Yu Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro Proc Am Assoc Cancer Res 48 2007 275
14. T.W. Synold, R.J. Morgan, E.M. Newman A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: a California Cancer consortium trial J Clin Oncol 23 2005 [Abstract 3036]
15. J. Cortes, L. Vahdat, J.L. Blum Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine J Clin Oncol 28 2010 3922 3928
16. C. Twelves, D. Loesch, J.L. Blum A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 28 2010 [Abstract CRA1004]
17. L.T. Vahdat, B. Pruitt, C.J. Fabian Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 27 2009 2954 2961
18. S. Goel, A.C. Mita, M. Mita A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid tumors Clin Cancer Res 15 2009 4207 4212
19. A.R. Tan, E.H. Rubin, D.C. Walton Phase I study of eribulin mesylate (E7389) administered once every 21 days in patients with advanced solid tumors Clin Cancer Res 15 2009 4213 4218
20. P. Therasse, S.G. Arbuck, E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
21. F.A. Shepherd, J. Dancey, R. Ramlau Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2000 2095 2103 (Pubitemid 30324363)
22. M. Krzakowski, J.Y. Douillard, R. Ramlau Phase III study of vinflunine versus docetaxel in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a platinum-containing regimen J Clin Oncol 25 2007 387